While Long et al. found that combination nivolumab and ipilimumab in melanoma brain metastases, patients with PD-L1 expression ≥1% had longer PFS than those with PD-L1 expression <1% (Long et al., 2018). This evidence concerns the gene CD274 and melanoma.